Skip to main content

Medical Injectables Program

Horizon Blue Cross Blue Shield of New Jersey is committed to providing your patients, our members, with access to high-quality health care services that are consistent with nationally recognized clinical criteria and guidelines.

As part of that commitment, Horizon BCBSNJ collaborates with Magellan Rx Management, a specialty pharmaceutical management company to administer our Medical Injectables Program (MIP). Magellan Rx Management conducts medical necessity and appropriateness reviews (MNARs) for specific injectable medications.

Hemophilia Drugs
Effective August 15, 2019, we will expand the scope of the MIP to include hemophilia drugs. Beginning for services to be provided on and after August 15, 2019, Magellan Rx Management will conduct medical necessity and appropriateness review (MNAR) for hemophilia drugs.

Hemophilia Case Review Form
As part of this program, rendering providers of hemophilia products must complete a Hemophilia Case Review Form prior to the dispensing of the first dose and prior to the dispensing of subsequent doses that will document:

  • Original prescription information
  • Requested amount to be dispensed (including specific vial sizes
  • Vial sizes available
  • Patient clinical history (including patient product inventory and bleed history)

This case review process will help ensure appropriate administration of medication, assay management, inventory management and patient engagement, as well as helping ensure that bleed history is appropriately documented and tracked.